Analyst Reco. Theravance Biopharma, Inc.

Equities

TBPH

KYG8807B1068

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
8.32 ^USD	-2.35%		-0.95%	-25.98%

Jun. 24	Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Pharmaceuticals Select Industry Index	CI
May. 23	Transcript : Theravance Biopharma, Inc. - Special Call

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	Apr. 12	MT
BTIG Starts Theravance Biopharma With Buy Rating, $21 Price Target	Apr. 12	MT
HC Wainwright Adjusts Price Target on Theravance Biopharma to $20 From $19, Keeps Buy Rating	23-05-09	MT
SVB Securities Adjusts Price Target on Theravance Biopharma to $14 From $12, Maintains Outperform Rating	22-11-17	MT
HC Wainwright Adjusts Price Target on Theravance Biopharma to $19 From $12, Maintains Buy Rating	22-11-08	MT
Theravance Biopharma Rises After SVB Securities Initiates Outperform Rating	22-05-23	MT
SVB Securities Initiates Theravance Biopharma at Outperform With $12 Price Target	22-05-23	MT
HC Wainwright Adjusts Theravance Biopharma's Price Target to $12 From $8, Reiterates Buy Rating	22-02-24	MT
JPMorgan Upgrades Theravance Biopharma to Neutral From Underweight, Lifts Price Target to $12 From $7	21-11-05	MT
THERAVANCE BIOPHARMA : Needham Downgrades Theravance Biopharma to Hold From Buy	21-09-16	MT
THERAVANCE BIOPHARMA : Baird Adjusts Theravance Biopharma PT to $7 From $10, Maintains Neutral Rating	21-09-16	MT
THERAVANCE BIOPHARMA : Morgan Stanley Adjusts Theravance Biopharma's Price Target to $10 from $14, Keeps Underweight Rating	21-09-16	MT
THERAVANCE BIOPHARMA : SVB Leerink Cuts Price Target on Theravance Biopharma to $10 From $29, Keeps Outperform Rating	21-09-16	MT
THERAVANCE BIOPHARMA : HC Wainwright Slashes Price Target on Theravance Biopharma to $8 From $21, Keeps Buy Rating	21-09-16	MT
ANALYST RECOMMENDATIONS : Activision Blizzard, Beyond Meat, Britvic, Las Vegas Sans, Unilever...	21-09-16
THERAVANCE BIOPHARMA : JPMorgan Downgrades Theravance Biopharma to Underweight From Overweight, Adjusts Price Target to $7 From $17	21-09-15	MT
ANALYST RECOMMENDATONS : Asos, Beazley, Factset, Hiscox, Next...	21-08-25
THERAVANCE BIOPHARMA : Morgan Stanley Downgrades Theravance Biopharma to Underweight From Overweight, Lowers PT to $14 From $27	21-08-24	MT
THERAVANCE BIOPHARMA : Evercore ISI Adjusts Theravance Biopharma PT to $21 From $30, Maintains Outperform Rating	21-08-24	MT
THERAVANCE BIOPHARMA : JPMorgan Adjusts Theravance Biopharma's Price Target to $23 From $27, Maintains Overweight Rating	21-08-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Theravance Biopharma, Inc.

Equities

TBPH

KYG8807B1068

Analyst Reco.

Filters